--- Source: patent_assignee_analysis.txt ---

Paul Janssen Patent Assignee Analysis

Overview

A search of Google Patents for inventor "Paul A. J. Janssen" reveals approximately 75 patents sorted by oldest first.

Assignee Patterns Identified

The search results show the following assignee breakdown:

| Assignee | Percentage |

|----------|------------|

| A. J. Janssen Paul (Individual) | 29.3% |

| Paul A J Janssen (Individual) | 18.6% |

| Janssen Pharmaceutica N.V. | Listed |

| Janssen Pharmaceutica Naamloze Vennootschap | Listed |

| Res Lab Dr C Janssen N V | Listed |

| Nl Combinatie Chem Ind | Listed |

Earliest Patents Analysis (Sorted by Oldest)

1. US2894033A - Antispasmodic (1959)

• Priority: 1955-11-15
• Filed: 1956-09-10
• Granted: 1959-07-07
• Assignee: Nl Combinatie Chem Ind (N.V. Nederlandsche Combinatie voor Chemische Industrie)
• Note: This is a DUTCH company, not Belgian

2. US2877156A - Anti-spasmodic preparation (1959)

• Priority: 1954-05-07
• Filed: 1957-04-12
• Granted: 1959-03-10
• Assignee: Nl Combinatie Chem Ind

3. US2881165A - alpha-alpha-diphenyl-gamma-hexamethyleneiminobutyramide (1959)

• Priority: 1956-06-29
• Filed: 1957-06-18
• Granted: 1959-04-07
• Assignee: Nl Combinatie Chem Ind
• Full text: "Paul A. J. Janssen, Vosselaar, near Turnhout, Belgium, and David K. De Jongh, Heemstede, Netherlands, assignors to N. V. Nederlandsche Combinatie voor Chemische Industrie, Amsterdam, Netherlands, a limited liability company"

4. US2898340A - 2,2-diaryl-omega-(4'-phenyl-1'-piperidino) alkanonitriles (1959)

• Priority: 1957-07-05
• Filed: 1958-03-14
• Granted: 1959-08-04
• Assignee: Paul A J Janssen (INDIVIDUAL)

5. US2973365A - 1-aroylalkyl-4-aryl-1, 2, 3, 6-tetrahydropyridines (1961)

• Priority: 1959-04-09
• Filed: 1959-04-09
• Granted: 1961-02-28
• Assignee: Paul A J Janssen (INDIVIDUAL)

6. US2979508A - Heterocyclic derivatives (1961)

• Priority: 1959-10-12
• Filed: 1959-10-12
• Granted: 1961-04-11
• Assignee: Paul A J Janssen (INDIVIDUAL)

7. US2997474A - 1-aryl-omega-(4-arylpiperazine) alkanols (1961)

• Priority: 1959-10-12
• Filed: 1959-10-12
• Granted: 1961-08-22
• Assignee: Paul A J Janssen (INDIVIDUAL)

8. US2973360A - Certain 1-(2-theonyl lower alkyl)-4-(heterocyclic substituted)-piperazines (1961)

• Priority: 1959-10-12
• Filed: 1959-10-12
• Granted: 1961-02-28
• Assignee: Paul A J Janssen (INDIVIDUAL)

Critical Findings

1. Earliest Patents Assigned to DUTCH Company (Not Belgian)

The earliest patents (1954-1957 priority dates) were assigned to N.V. Nederlandsche Combinatie voor Chemische Industrie - a Dutch company based in Amsterdam, Netherlands.

This raises the question: Why were Paul Janssen's earliest patents assigned to a Dutch company rather than his father's Belgian company?

2. Shift to Individual Assignee (1957-1959)

Starting from 1957, patents began to be assigned to Paul Janssen as an individual, not to any company.

3. Nearly 50% of Patents Assigned to Individual

According to the Google Patents breakdown:

• 29.3% assigned to "A. J. Janssen Paul"
• 18.6% assigned to "Paul A J Janssen"
• Total: ~48% assigned to Paul Janssen as an individual

4. Janssen Pharmaceutica N.V. Appears Later

The company "Janssen Pharmaceutica N.V." appears as an assignee, but this name was only adopted in 1964 (after the J&J acquisition).

Questions Raised

• Why were the earliest patents (1954-1957) assigned to a Dutch company rather than the Belgian family business?
• Why did Paul Janssen file nearly half his patents as an individual rather than through a company?
• What was the relationship between Paul Janssen and N.V. Nederlandsche Combinatie voor Chemische Industrie?
• Did the Belgian company (NV Produkten Richter / Richter-Eupharma) have any patent portfolio?

---

CRITICAL FINDING: Dual Assignee Structure (1956)

US2894033A - Earliest Patent Details

From the patent text: > "Paul A. J. Janssen, Turnhout, Belgium, and David K. de Jongh, Haarlem, Netherlands, assignors to N. V. Nederlandsche Combinatie voor Chemische Industrie, Amsterdam, Netherlands, a company of Belgium, and Laboratoria Pharmaceutica Dr. C. Janssen, N.V., Turnhout, Belgium, a company of Belgium"

Key Observations:

• TWO ASSIGNEES - The patent was assigned to BOTH:

- N.V. Nederlandsche Combinatie voor Chemische Industrie (Amsterdam, Netherlands)

- Laboratoria Pharmaceutica Dr. C. Janssen, N.V. (Turnhout, Belgium)

• INCORRECT JURISDICTION - The patent text describes the Dutch company as "a company of Belgium" - this appears to be an error, as the company was based in Amsterdam, Netherlands.

• CO-INVENTOR - David K. de Jongh from Haarlem, Netherlands was a co-inventor, suggesting a Dutch-Belgian collaboration.

• PRIORITY CLAIM - "Claims priority, application Netherlands November 15, 1955" - The original priority was filed in the NETHERLANDS, not Belgium.

Current Assignee (Updated):

• Janssen Pharmaceutica NV
• Nederlandsche Combinatie voor Chemische Industrie NV

Timeline:

• Priority Date: November 15, 1955 (Netherlands)
• Filed: September 10, 1956
• Granted: July 7, 1959

---

Questions Raised by This Finding:

• What was the relationship between the Dutch and Belgian companies?

- Were they joint ventures?

- Was the Dutch company licensing from the Belgian company?

- Was the Belgian company a subsidiary of the Dutch company?

• Why was the priority filed in the Netherlands, not Belgium?

- If Janssen was a Belgian company, why file first in the Netherlands?

• Who was David K. de Jongh?

- A Dutch co-inventor from Haarlem

- What was his relationship to Paul Janssen?

- Was he affiliated with the Dutch company?

• The "company of Belgium" error

- The Dutch company is incorrectly described as "a company of Belgium"

- Was this intentional misrepresentation or a clerical error?